Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting

By Keetch D.W.   Andriole G.L.   Ratliff T.L.   Catalona W.J.  

Urology, Vol. 50, Iss. 6, 1997-12 ,pp. : 901-905

Elsevier

Access to resources Recommend Favorite

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

By Elhilali M.M.   Ramsey E.W.   Barkin J.   Casey R.W.   Boake R.C.   Beland G.   Fradet Y.   Trachtenberg J.   Orovan W.L.   Schick E.   Klotz L.H.  

Urology, Vol. 47, Iss. 3, 1996-03 ,pp. : 335-342

Elsevier

Access to resources Recommend Favorite

Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia

By Cadeddu J.A.   Pearson J.D.   Lee B.R.   Landis P.   Partin A.W.   Epstein J.I.   Carter H.B.  

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 795-800

Elsevier

Access to resources Recommend Favorite

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia - relationship among symptoms, prostate volume and peak urinary flow rate

By Roehrborn C.G.   Boyle P.   Gould A.L.   Waldstreicher J.  

Urology, Vol. 53, Iss. 3, 1999-03 ,pp. : 581-589

Elsevier

Access to resources Recommend Favorite

Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia

By Feneley M.R.   Dunsmuir W.D.   Pearce J.   Kirby R.S.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 658-663

Elsevier

Access to resources Recommend Favorite